Low Back PainNCT06356844
The Effect of Resolvins on the Resolve of Inflammatory Low Back Pain
A study testing Resolvin supplement in people with Low Back Pain and Inflammatory Response, run by Bezmialem Vakif University at 2 sites in Turkey (Türkiye).
Trial summary
Brief Summary: Inflammatory back pain is a chronic condition localized in the axial spine and sacroiliac joints.1 It often accompanies mechanical issues like lumbar disc herniation. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Low Back Pain, Inflammatory Response, Lumbar Disc Herniation
- What is being tested?
- Resolvin supplement
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 27 Feb 2024to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA I-II-III
- Patients who underwent caudal epidural injection, facet joint injection and transforaminal injection due to lumbar disc herniation
Who cannot join
- Patients with known allergies to the drugs to be used in treatment
- Infection near the puncture site
- Known clotting disorders
- Alcohol and drug use
- Those who have used fish oil before
- Disorder of consciousness
Show all 11Show fewer
- Liver failure, renal failure, advanced cardiac failure
- Uncontrolled diabetes mellitus
- Morbid obesity (body mass index (BMI) > 35 kg m-2)
- Female patients during pregnancy and breastfeeding
- Not approving the informed consent form
Trial locations and contacts
2 sites in 1 country.
Turkey (Türkiye)2 sites, 1 recruiting
- Recruiting
Aylin Ceren Şanlı
Istanbul
Aylin C Sanli, Asist Dr, +0905496522412, aylincerensanli@hotmail.com
- Completed
Aylin Ceren
Istanbul
About this study
Official title: The Effect of Adding Oral Resolvins to Patients Undergoing Transforaminal Epidural Steroid Injection for Low Back Pain Treatment"
Brief Summary: Inflammatory back pain is a chronic condition localized in the axial spine and sacroiliac joints.1 It often accompanies mechanical issues like lumbar disc herniation. While non-surgical interventions such as medication, physiotherapy, and epidural steroid injections are typically the initial approach, surgical options may be considered if these prove ineffective.2 Resolvins, derived from omega-3 fatty acids, have shown promise in reducing inflammation and pain. They help to resolve inflammatory responses, promote tissue repair, and decrease disc size, potentially reducing the need for surgery.3,4 This clinical trial aims to evaluate the efficacy of adding oral resolvins to transforaminal epidural steroid injections for treating lumbar disc herniation (LDH) The control group (Group C: n=25) will receive epidural steroids, while the study group (Group R: n=25) will receive both oral omega-3 supplementation and epidural steroids on the same day. Additionally, the study group will continue taking oral omega-3 supplements for six months.
The primary outcome measure will be changes in protruded/extruded disc size assessed via MRI, with secondary outcomes including pain levels measured by the Numeric Rating Scale (NRS) and serum cytokine levels (IL-6, IL-17, IL-1 beta, TNF-alpha) over the study period.
Discussion: This trial anticipates that combining the anti-inflammatory properties of resolvins with epidural steroid injection will provide a beneficial treatment for patients suffering from inflammatory low back pain.
Read the detailed description
In the general population, about 70% to 80% of adults experience low back pain at some point in their lives. In primary care, the point prevalence ranges from 16% to 55%, making low back pain the most common neuropathic pain.5 In this context, radiculopathy is a common type of neuropathic pain. Pain can arise not only from direct mechanical pressure, such as from a herniated disc or degenerated bone, but also from inflammation and its associated proinflammatory cytokines. Inflammatory mediators contributing to neuropathic pain include nucleus pulpous cells and sequestered macrophages.6,7 Cytokines, as regulatory proteins acting as pro-inflammatory biomarkers, modulate the inflammatory response of all immune system cells during instances of inflammation.8 Despite its high prevalence, the response to medical treatment, physical therapy, and epidural steroid injections varies widely. For years, the widely accepted explanation for this variability has been the complex mechanisms involved in pain transmission. However, in recent years, it has been increasingly recognized that the lack of resolution of neuroinflammatory cells and mediators may be the most significant factor contributing to the varying treatment responses observed in individuals.9 Resolvins are specialized compounds derived from DHA (docosahexaenoic acid) and omega-3 fatty acids. Prior research indicates that certain resolvin subtypes, particularly D and E, aid in pain reduction by facilitating inflammation resolution. These specialized compounds, known as SPMs (Specialized pro-resolving mediators), regulate immune cell functions, modulate cytokine levels, and promote tissue repair mechanisms. 9,10 The aim of this study is to evaluate the impact of orally administered resolvins, in conjunction with epidural steroid injection, over a period of 6 months, on pain intensity and cytokine release during the remission phase. These effects will be assessed using magnetic resonance imaging.
Materials and Methods This clinical trial will be a randomized, controlled trial conducted at Bezmialem Vakıf University Hospital. A total of 30 patients will be enrolled in the study at this hospital. The study has received approval from the Ethics Boards of Bezmialem Vakif University Hospital. Prior to participation, all study participants will provide written informed consent.
Inclusion criteria: Patients must be classified as ASA I-II-III, aged between 18-75, presenting to the Algology department with low back pain due to lumbar disc herniation, have a pain intensity of ≥4 on the 0-10 scale pain NRS for low back pain, and/or experience radiating pain from the lower extremities caused by LDH (MRI scan confirmed lumbar disc herniation in our hospital).
Exclusion Criteria: Patients with known allergies to the drugs to be used in treatment, infection near the puncture site, known clotting disorders, alcohol and drug use, those who have used fish oil before, disorder of consciousness, liver failure, renal failure, advanced cardiac failure, uncontrolled diabetes mellitus, morbid obesity (body mass index (BMI) > 35 kg/m²), female patients during pregnancy and breastfeeding, not approving the informed consent form.
30 patients scheduled for caudal epidural injection, transforaminal epidural steroid injection will be included. Patients will be randomly assigned to two groups (Group K: control group, Group R: patients treated with resolvin) using opaque sealed envelopes. The physician performing the procedure (AT) and collecting data (AB) will be blinded to the groups. In Group R, treatment with 700 mg resolvin (omega DHA) will commence on the day the procedural decision is made.
Intervention: After the patient is admitted to the ward on the morning of the procedure, they will undergo routine blood tests, including a hemogram, APTT, INR, CRP, and sedimentation test. Once the results are obtained, the patient will be sent for the operation. Upon arrival in the operating room, basic monitoring including ECG, non-invasive blood pressure, and pulse oximetry will be performed. The operating room will be standardized, and normothermia will be maintained. Patients will be positioned prone on the operating table, and nasal oxygen support at 4L/min will be provided. After administering sedation and analgesia, prophylactic antibiotics will be given. The operative site will be prepared with an antiseptic solution and draped sterilely. All procedures are performed with the assistance of ultrasonography using a convex probe. After local anesthesia is applied to the areas to be treated, the procedure begins with a caudal epidural injection consisting of 40mg depomedrol, 60mg lidocaine, 20mg bupivacaine, and 100mg magnesium. Following this, the transforaminal epidural injection is administered with 2mg dexamethasone, 20mg lidocaine, 5mg bupivacaine, and 100mg magnesium. The same doses are applied to the facet insertion as the needle is withdrawn." After completion of the procedure, patients will be monitored in the recovery room for half an hour, followed by mobilization and transfer to the ward. Stable hemodynamics and absence of neurological deficits and any other complications (nausea, bradycardia, hypotension, urinary incontinence, drowsiness, bleeding, neurological deficit, edema, dyspeptic complaints due to fish oil or steroids) will warrant discharge after 6 hours.
Blood samples will be collected from the patients on the morning of the procedure day, during the one-week follow-up appointment after the procedure, and during the six-month follow-up along with MRI. Additionally, all medications used by patients during this period will be recorded.
Primary The primary objective of this study: Magnetic Resonance Imaging (MRI) is the gold standard for diagnosing lumbar disc herniation, with a diagnostic accuracy rate of 97%. It is also a crucial parameter used to determine the need for surgical intervention. MRI imaging will be used to measure the size of herniation preoperatively and at the 6th postoperative month by a radiologist who is blinded to the patient groups (AA).
Secondary objective of this study:
- NRS Score: The Numeric Rating Scale (NRS) is a unidimensional scale using 11 numbers (ranging from 0 to 10) to assess pain intensity. Patients are asked to select the number that best represents their pain intensity, with 0 indicating no pain and 10 indicating the worst (unbearable) pain. Pain intensity will be assessed by having patients choose the number that corresponds to their pain intensity. Pain levels of all patients at the 1st postoperative week, 1st month, and 6th month will be recorded based on the NRS score by an anesthesiologist who is blinded to the patient groups.
- Cytokines: Cytokines are small proteins synthesized by cells responsible for intercellular communication and interaction. They include various subtypes such as interleukins. The majority of studies found a positive association between the pro-inflammatory biomarkers CRP, IL-6, TNF-a, and low back pain. Blood tests for cytokine levels (Interleukin-6, Interleukin-17, Interleukin-1beta, TNF-alpha) were conducted preoperatively, at the 1st postoperative week, and at the 6th month by a medical biochemist who was blinded to the patient groups."
Statistics: Power analysis: Based on previous studies and considering an average difference of 0.50 units between groups with 80% power at a 95% confidence level, the minimum sample size was determined as 13 individuals per group, totaling 26 participants. Qualitative variables will be presented as numbers and percentages, while quantitative variables will be expressed as mean, standard deviation, median, minimum, and maximum. The relationships between qualitative variables will be examined using Pearson chi-square or Fisher exact chi-square tests. Normal distribution of quantitative variables will be assessed using the Kolmogorov-Smirnov test, and homogeneity of variance will be evaluated using the Levene test. Differences between the means of two independent groups will be analyzed using the Student's t-test, while median comparisons will be conducted using the Mann-Whitney U test. Paired t-tests and Wilcoxon signed-rank tests will be employed for comparing means and medians of two dependent groups, respectively. Following univariate analyses, appropriate regression analyses will be utilized based on the data structure. Calculations will be performed using the SPSS software package (version), with a statistical significance level set at 0.05.
Discussion: This trial anticipates that combining the anti-inflammatory properties of resolvins with epidural steroid injection will provide a beneficial treatment for patients suffering from inflammatory low back pain. This study demonstrates that two separate mechanisms result, including the decrease in cell recruitment to the inflammation site with steroids, which reflects an anti-inflammatory effect, and increases in cell exit with resolvin, which reflects a pro-resolution effect.
References
- Lassiter W, Allam AE. Inflammatory Back Pain. Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2023 Jan-. 2022 Sep 5. PMID: 30969575.
- Taso M, Sommernes JH, Kolstad F, Sundseth J, Bjorland S, Pripp AH, Zwart JA, Brox JI. A randomized controlled trial comparing the effectiveness of surgical and nonsurgical treatment for cervical radiculopathy. BMC Musculoskeletal Disorder. 2020 Mar 16;21(1):171. PMID: 32178655; PMCID: PMC7076994.
- Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci. 2011 Nov;34(11):599-609. PMID: 21963090; PMCID: PMC3200462.
- Liu C, Fan D, Lei Q, Lu A, He X. Roles of Resolvins in Chronic Inflammatory Response. Int J Mol Sci. 2022 Nov 28;23(23):14883. PMID: 36499209; PMCID: PMC9738788.
- Yoshiaki Ota, Michael Connolly, Ashok Srinivasan, John Kim, Aristides A Capizzano, Toshio Moritani. Mechanisms and origins of spinal pain: from molecules to anatomy, with diagnostic clues and imaging findings Radiographic. Jul-Aug 2020;40(4):1163-1181.
- Sowa GA, Coelho JP, Vo NV, Pacek C, Westrick E, Kang JD. Cells from degenerative intervertebral discs demonstrate unfavorable responses to mechanical and inflammatory stimuli: a pilot study. Am J Phys Med Rehabil 2012;91:846-855.
- Videman T, Saarela J, Kaprio J, et al. Associations of 25 structural, degradative, and inflammatory candidate genes with lumbar disc desiccation, bulging, and height narrowing. Arthritis Rheum 2009;60:470-481.8
- R van den Berg 1, E M Jongbloed 2, E I T de Schepper 2, S M A Bierma-Zeinstra 3, B W Koes 2, P A J Luijsterburg. The association between pro-inflammatory biomarkers and nonspecific low back pain: a systematic review Spine J 2018 Nov;18(11):2140-215
- Ru-Rong Ji1, Zhen-Zhong Xu1, Gary Strichartz1, and Charles N. Serhan2. Emerging Roles of Resolvins in the Resolution of Inflammation and Pain. Trends Neurosci. 2011 November; 34(11): 599-609. doi:10.1016/j.tins.2011.08.005.
- Chang Liu 1,2, Dancai Fan 3 , Qian Lei 1,3, Aiping Lu 1,4,5,* and Xiaojuan He 3,*. Roles of Resolvins in Chronic Inflammatory Response. Int. J. Mol. Sci. 2022, 23, 14883. https://doi.org/10.3390/ijms232314883.
- Simon C, Le Corroller T, Pauly V, Creze M, Champsaur P, Guenoun D. Intradiscal oxygen-ozone therapy for the treatment of symptomatic lumbar disc herniation: A preliminary study. J Neuroradiol. 2022 Mar;49(2):180-186. doi: 10.1016/j.neurad.2021.09.004. Epub 2021 Oct 8. PMID: 34634298.
- Conditions
- Low Back Pain, Inflammatory Response, Lumbar Disc Herniation
- Being tested
- Resolvin supplement
- Keywords
- Transforaminal Steroid İnjection, Resolvin Therapy, Magnetic resonance imaging, Lumbar disc herniation, Cytokines level
- Medical subject headings
- Low Back Pain, Intervertebral Disc Displacement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resolvin supplementDietary supplement
Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
| Study group | Role | What they receive |
|---|---|---|
| Treated with resolvin | Active comparator | Transforaminal steroid injection with ultrasound and resolvin therapy Receives: Dietary Supplement: Resolvin supplement |
| No resolvin treatment | No intervention | Transforaminal steroid injection with ultrasound and no resolvin treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
changes in protruded/extruded disc size
measure will be changes in protruded/extruded disc size assessed via MRI
Measured: Preoperatif, postoperative 6th month
Secondary outcomes (2)
Pain intensity score
Postoperative pain assessed using a numeric rating scale 0 to 10 (0 = unsatisfied; 10 =very satisfied) and VAS (visual analogue scale)
Measured: Preoperative, postoperative 1st week, postoperative 1th month, postoperative 6th month
Cytokine markers
Evaluating Interleukin-6, Interleukin-17, Interleukin-1 beta, TNF-alpha marker results
Measured: Preoperative, postoperative 1st week, postoperative 6th month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2024
- Study start27 Feb 2024
- Primary completionNov 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Low Back PainStudies of the same condition, open and under way.
- More trials run by Bezmialem Vakif UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bezmialem Vakif University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aylin Ceren Sanli, Bezmialem Vakif University
- Investigators
- zübeyde özdemir, Study chair, ethics committee chairman
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06356844
- Sponsor's protocol ID
- 27.02.2023-E.142568
- Status last verified
- May 2024
- First submitted
- 5 Mar 2024
- Last updated
- 17 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: yes
Study at a glance
From the registry record, last updated by the sponsor on 17 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Adding Oral Resolvins to Patients Undergoing Transforaminal Epidural Steroid Injection for Low Back Pain Treatment"
- ClinicalTrials.gov ID
- NCT06356844
- Acronym / sponsor ID
- 27.02.2023-E.142568
- Conditions
- Low Back Pain, Inflammatory Response, Lumbar Disc Herniation
- Keywords
- Transforaminal Steroid İnjection, Resolvin Therapy, Magnetic resonance imaging, Lumbar disc herniation, Cytokines level
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Bezmialem Vakif UniversityUniversity, hospital or other
- Study start
- 27 Feb 2024 (actual)
- Primary completion
- Nov 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 10 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary: Inflammatory back pain is a chronic condition localized in the axial spine and sacroiliac joints.1 It often accompanies mechanical issues like lumbar disc herniation. While non-surgical interventions such as medication, physiotherapy, and epidural steroid injections are typically the initial approach, surgical options may be considered if these prove ineffective.2 Resolvins, derived from omega-3 fatty acids, have shown promise in reducing inflammation and pain. They help to resolve inflammatory responses, promote tissue repair, and decrease disc size, potentially reducing the need for surgery.3,4 This clinical trial aims to evaluate the efficacy of adding oral resolvins to transforaminal epidural steroid injections for treating lumbar disc herniation (LDH) The control group (Group C: n=25) will receive epidural steroids, while the study group (Group R: n=25) will receive both oral omega-3 supplementation and epidural steroids on the same day. Additionally, the study group will continue taking oral omega-3 supplements for six months.
The primary outcome measure will be changes in protruded/extruded disc size assessed via MRI, with secondary outcomes including pain levels measured by the Numeric Rating Scale (NRS) and serum cytokine levels (IL-6, IL-17, IL-1 beta, TNF-alpha) over the study period.
Discussion: This trial anticipates that combining the anti-inflammatory properties of resolvins with epidural steroid injection will provide a beneficial treatment for patients suffering from inflammatory low back pain.
Detailed description
In the general population, about 70% to 80% of adults experience low back pain at some point in their lives. In primary care, the point prevalence ranges from 16% to 55%, making low back pain the most common neuropathic pain.5 In this context, radiculopathy is a common type of neuropathic pain. Pain can arise not only from direct mechanical pressure, such as from a herniated disc or degenerated bone, but also from inflammation and its associated proinflammatory cytokines. Inflammatory mediators contributing to neuropathic pain include nucleus pulpous cells and sequestered macrophages.6,7 Cytokines, as regulatory proteins acting as pro-inflammatory biomarkers, modulate the inflammatory response of all immune system cells during instances of inflammation.8 Despite its high prevalence, the response to medical treatment, physical therapy, and epidural steroid injections varies widely. For years, the widely accepted explanation for this variability has been the complex mechanisms involved in pain transmission. However, in recent years, it has been increasingly recognized that the lack of resolution of neuroinflammatory cells and mediators may be the most significant factor contributing to the varying treatment responses observed in individuals.9 Resolvins are specialized compounds derived from DHA (docosahexaenoic acid) and omega-3 fatty acids. Prior research indicates that certain resolvin subtypes, particularly D and E, aid in pain reduction by facilitating inflammation resolution. These specialized compounds, known as SPMs (Specialized pro-resolving mediators), regulate immune cell functions, modulate cytokine levels, and promote tissue repair mechanisms. 9,10 The aim of this study is to evaluate the impact of orally administered resolvins, in conjunction with epidural steroid injection, over a period of 6 months, on pain intensity and cytokine release during the remission phase. These effects will be assessed using magnetic resonance imaging.
Materials and Methods This clinical trial will be a randomized, controlled trial conducted at Bezmialem Vakıf University Hospital. A total of 30 patients will be enrolled in the study at this hospital. The study has received approval from the Ethics Boards of Bezmialem Vakif University Hospital. Prior to participation, all study participants will provide written informed consent.
Inclusion criteria: Patients must be classified as ASA I-II-III, aged between 18-75, presenting to the Algology department with low back pain due to lumbar disc herniation, have a pain intensity of ≥4 on the 0-10 scale pain NRS for low back pain, and/or experience radiating pain from the lower extremities caused by LDH (MRI scan confirmed lumbar disc herniation in our hospital).
Exclusion Criteria: Patients with known allergies to the drugs to be used in treatment, infection near the puncture site, known clotting disorders, alcohol and drug use, those who have used fish oil before, disorder of consciousness, liver failure, renal failure, advanced cardiac failure, uncontrolled diabetes mellitus, morbid obesity (body mass index (BMI) > 35 kg/m²), female patients during pregnancy and breastfeeding, not approving the informed consent form.
30 patients scheduled for caudal epidural injection, transforaminal epidural steroid injection will be included. Patients will be randomly assigned to two groups (Group K: control group, Group R: patients treated with resolvin) using opaque sealed envelopes. The physician performing the procedure (AT) and collecting data (AB) will be blinded to the groups. In Group R, treatment with 700 mg resolvin (omega DHA) will commence on the day the procedural decision is made.
Intervention: After the patient is admitted to the ward on the morning of the procedure, they will undergo routine blood tests, including a hemogram, APTT, INR, CRP, and sedimentation test. Once the results are obtained, the patient will be sent for the operation. Upon arrival in the operating room, basic monitoring including ECG, non-invasive blood pressure, and pulse oximetry will be performed. The operating room will be standardized, and normothermia will be maintained. Patients will be positioned prone on the operating table, and nasal oxygen support at 4L/min will be provided. After administering sedation and analgesia, prophylactic antibiotics will be given. The operative site will be prepared with an antiseptic solution and draped sterilely. All procedures are performed with the assistance of ultrasonography using a convex probe. After local anesthesia is applied to the areas to be treated, the procedure begins with a caudal epidural injection consisting of 40mg depomedrol, 60mg lidocaine, 20mg bupivacaine, and 100mg magnesium. Following this, the transforaminal epidural injection is administered with 2mg dexamethasone, 20mg lidocaine, 5mg bupivacaine, and 100mg magnesium. The same doses are applied to the facet insertion as the needle is withdrawn." After completion of the procedure, patients will be monitored in the recovery room for half an hour, followed by mobilization and transfer to the ward. Stable hemodynamics and absence of neurological deficits and any other complications (nausea, bradycardia, hypotension, urinary incontinence, drowsiness, bleeding, neurological deficit, edema, dyspeptic complaints due to fish oil or steroids) will warrant discharge after 6 hours.
Blood samples will be collected from the patients on the morning of the procedure day, during the one-week follow-up appointment after the procedure, and during the six-month follow-up along with MRI. Additionally, all medications used by patients during this period will be recorded.
Primary The primary objective of this study: Magnetic Resonance Imaging (MRI) is the gold standard for diagnosing lumbar disc herniation, with a diagnostic accuracy rate of 97%. It is also a crucial parameter used to determine the need for surgical intervention. MRI imaging will be used to measure the size of herniation preoperatively and at the 6th postoperative month by a radiologist who is blinded to the patient groups (AA).
Secondary objective of this study:
- NRS Score: The Numeric Rating Scale (NRS) is a unidimensional scale using 11 numbers (ranging from 0 to 10) to assess pain intensity. Patients are asked to select the number that best represents their pain intensity, with 0 indicating no pain and 10 indicating the worst (unbearable) pain. Pain intensity will be assessed by having patients choose the number that corresponds to their pain intensity. Pain levels of all patients at the 1st postoperative week, 1st month, and 6th month will be recorded based on the NRS score by an anesthesiologist who is blinded to the patient groups.
- Cytokines: Cytokines are small proteins synthesized by cells responsible for intercellular communication and interaction. They include various subtypes such as interleukins. The majority of studies found a positive association between the pro-inflammatory biomarkers CRP, IL-6, TNF-a, and low back pain. Blood tests for cytokine levels (Interleukin-6, Interleukin-17, Interleukin-1beta, TNF-alpha) were conducted preoperatively, at the 1st postoperative week, and at the 6th month by a medical biochemist who was blinded to the patient groups."
Statistics: Power analysis: Based on previous studies and considering an average difference of 0.50 units between groups with 80% power at a 95% confidence level, the minimum sample size was determined as 13 individuals per group, totaling 26 participants. Qualitative variables will be presented as numbers and percentages, while quantitative variables will be expressed as mean, standard deviation, median, minimum, and maximum. The relationships between qualitative variables will be examined using Pearson chi-square or Fisher exact chi-square tests. Normal distribution of quantitative variables will be assessed using the Kolmogorov-Smirnov test, and homogeneity of variance will be evaluated using the Levene test. Differences between the means of two independent groups will be analyzed using the Student's t-test, while median comparisons will be conducted using the Mann-Whitney U test. Paired t-tests and Wilcoxon signed-rank tests will be employed for comparing means and medians of two dependent groups, respectively. Following univariate analyses, appropriate regression analyses will be utilized based on the data structure. Calculations will be performed using the SPSS software package (version), with a statistical significance level set at 0.05.
Discussion: This trial anticipates that combining the anti-inflammatory properties of resolvins with epidural steroid injection will provide a beneficial treatment for patients suffering from inflammatory low back pain. This study demonstrates that two separate mechanisms result, including the decrease in cell recruitment to the inflammation site with steroids, which reflects an anti-inflammatory effect, and increases in cell exit with resolvin, which reflects a pro-resolution effect.
References
- Lassiter W, Allam AE. Inflammatory Back Pain. Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2023 Jan-. 2022 Sep 5. PMID: 30969575.
- Taso M, Sommernes JH, Kolstad F, Sundseth J, Bjorland S, Pripp AH, Zwart JA, Brox JI. A randomized controlled trial comparing the effectiveness of surgical and nonsurgical treatment for cervical radiculopathy. BMC Musculoskeletal Disorder. 2020 Mar 16;21(1):171. PMID: 32178655; PMCID: PMC7076994.
- Ji RR, Xu ZZ, Strichartz G, Serhan CN. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci. 2011 Nov;34(11):599-609. PMID: 21963090; PMCID: PMC3200462.
- Liu C, Fan D, Lei Q, Lu A, He X. Roles of Resolvins in Chronic Inflammatory Response. Int J Mol Sci. 2022 Nov 28;23(23):14883. PMID: 36499209; PMCID: PMC9738788.
- Yoshiaki Ota, Michael Connolly, Ashok Srinivasan, John Kim, Aristides A Capizzano, Toshio Moritani. Mechanisms and origins of spinal pain: from molecules to anatomy, with diagnostic clues and imaging findings Radiographic. Jul-Aug 2020;40(4):1163-1181.
- Sowa GA, Coelho JP, Vo NV, Pacek C, Westrick E, Kang JD. Cells from degenerative intervertebral discs demonstrate unfavorable responses to mechanical and inflammatory stimuli: a pilot study. Am J Phys Med Rehabil 2012;91:846-855.
- Videman T, Saarela J, Kaprio J, et al. Associations of 25 structural, degradative, and inflammatory candidate genes with lumbar disc desiccation, bulging, and height narrowing. Arthritis Rheum 2009;60:470-481.8
- R van den Berg 1, E M Jongbloed 2, E I T de Schepper 2, S M A Bierma-Zeinstra 3, B W Koes 2, P A J Luijsterburg. The association between pro-inflammatory biomarkers and nonspecific low back pain: a systematic review Spine J 2018 Nov;18(11):2140-215
- Ru-Rong Ji1, Zhen-Zhong Xu1, Gary Strichartz1, and Charles N. Serhan2. Emerging Roles of Resolvins in the Resolution of Inflammation and Pain. Trends Neurosci. 2011 November; 34(11): 599-609. doi:10.1016/j.tins.2011.08.005.
- Chang Liu 1,2, Dancai Fan 3 , Qian Lei 1,3, Aiping Lu 1,4,5,* and Xiaojuan He 3,*. Roles of Resolvins in Chronic Inflammatory Response. Int. J. Mol. Sci. 2022, 23, 14883. https://doi.org/10.3390/ijms232314883.
- Simon C, Le Corroller T, Pauly V, Creze M, Champsaur P, Guenoun D. Intradiscal oxygen-ozone therapy for the treatment of symptomatic lumbar disc herniation: A preliminary study. J Neuroradiol. 2022 Mar;49(2):180-186. doi: 10.1016/j.neurad.2021.09.004. Epub 2021 Oct 8. PMID: 34634298.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treated with resolvin | Active comparator | Dietary Supplement: Resolvin supplementTransforaminal steroid injection with ultrasound and resolvin therapy |
| No resolvin treatment | No intervention | –Transforaminal steroid injection with ultrasound and no resolvin treatment |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- ASA I-II-III
- Patients who underwent caudal epidural injection, facet joint injection and transforaminal injection due to lumbar disc herniation
Key exclusion criteria (11 listed)
- Patients with known allergies to the drugs to be used in treatment
- Infection near the puncture site
- Known clotting disorders
- Alcohol and drug use
- Those who have used fish oil before
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resolvin supplementTransforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively. | Dietary supplement | Treated with resolvin |
Primary outcome
changes in protruded/extruded disc size
Time frame: Preoperatif, postoperative 6th month
measure will be changes in protruded/extruded disc size assessed via MRI
2 secondary outcomes
Pain intensity score
Time frame: Preoperative, postoperative 1st week, postoperative 1th month, postoperative 6th month
Cytokine markers
Time frame: Preoperative, postoperative 1st week, postoperative 6th month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 May 2024.
- Individual participant dataSharing planned: Undecided. yes
Related trials for Low Back Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Not yet recruiting
Effect of Lumbar Stabilization Exercises With and Without YTWL (Scapular Stabilization Exercises) on Reducing Chronic Low Back Pain and Related Disability. A Randomized Clinical Trial,
Chronic Non Specific Mechanical Low Back Pain
Not yet recruiting
Comparing Non-Medicine Strategies for Improving Low Back Pain
Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Not yet recruiting
Effects of Whole-Body Vibration and Cervical Stabilization With Core Stabilization in Young Adults With Non-Specific Low Back Pain
Nonspecific Low Back Pain
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
zübeyde özdemir study chair
ethics committee chairman
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resolvin supplement in people with Low Back Pain and Inflammatory Response, run by Bezmialem Vakif University at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact zübeyde özdemir (+90 2125232288 ext. 3238, etikkurul@bezmialem.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
changes in protruded/extruded disc size (time frame: Preoperatif, postoperative 6th month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.